0000905718-22-000484.txt : 20220323
0000905718-22-000484.hdr.sgml : 20220323
20220323173038
ACCESSION NUMBER: 0000905718-22-000484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220321
FILED AS OF DATE: 20220323
DATE AS OF CHANGE: 20220323
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abingworth LLP
CENTRAL INDEX KEY: 0001397144
STATE OF INCORPORATION: X0
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39138
FILM NUMBER: 22764009
BUSINESS ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
BUSINESS PHONE: 44 (0)20 7534 1500
MAIL ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jasper Therapeutics, Inc.
CENTRAL INDEX KEY: 0001788028
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 842984849
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 BRIDGE PKWY SUITE #102
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 6505491400
MAIL ADDRESS:
STREET 1: 2200 BRIDGE PKWY SUITE #102
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Amplitude Healthcare Acquisition Corp
DATE OF NAME CHANGE: 20190912
4
1
jasper_fm4mar212022.xml
X0306
4
2022-03-21
0
0001788028
Jasper Therapeutics, Inc.
JSPR
0001397144
Abingworth LLP
PRINCES HOUSE 38 JERMYN STREET
LONDON
X0
SW1Y 6DN
UNITED KINGDOM
0
0
1
0
Stock Option (right to buy)
3.54
2022-03-21
4
A
0
78045
0.00
A
2032-03-21
Voting Common Stock
78045
78045
I
See footnotes
Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII.
The option (the "Option") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person.
ABV VII may be deemed the indirect beneficial owner of the Option, and Mr. von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Mr. von Emster, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ John Heard
2022-03-23